Evgen Pharma plc is a United Kingdom-based clinical-stage drug development company. The Company is focused on the clinical development of sulforaphane-based medicines for the treatment of cancer and inflammatory diseases. Its Sulforadex technology enables sulforaphane to be delivered as a stable, solid, active ingredient in an oral pharmaceutical product. Its lead drug, SFX-01, exploits sulforaphane’s activity in three separate biochemical pathways, such as inhibition of STAT3 and SHP2, of importance in controlling cancers metastases, and up-regulation of Nrf2, a pathway of significance in several different diseases. The Company pipeline includes SFX-01 and breast cancer, SFX-01 and glioma, and SFX-01 and SHP2. SFX-01 for the treatment of metastatic breast cancer and acute respiratory distress syndrome. The Company is also researching a range of synthetic, stabilized novel analogues of sulforaphane to advance the pharmaceuticals.